Tetraphase Pharmaceuticals (TTPH) Short Interest Ratio & Short Volume

Short interest is the volume of Tetraphase Pharmaceuticals shares that have been sold short but have not yet been closed out or covered. As of July 31st, investors have sold 43,700 shares of TTPH short. 0.81% of Tetraphase Pharmaceuticals' shares are currently sold short. Learn More on Tetraphase Pharmaceuticals' current short interest.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 0.81% of Tetraphase Pharmaceuticals' floating shares are currently sold short.

Tetraphase Pharmaceuticals saw a decline in short interest in the month of July. As of July 31st, there was short interest totaling 43,700 shares, a decline of 80.0% from the previous total of 219,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

Tetraphase Pharmaceuticals currently has issued a total of 7,263,000 shares. Some of Tetraphase Pharmaceuticals' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Tetraphase Pharmaceuticals currently has a public float of 5,420,000 shares.

0.81% of Tetraphase Pharmaceuticals' shares are currently sold short. Here is how the short interest of companies in the sector of "medical" compare to Tetraphase Pharmaceuticals: Talphera, Inc. (0.65%), Cocrystal Pharma, Inc. (0.02%), Kiora Pharmaceuticals, Inc. (0.31%), Aytu BioPharma, Inc. (7.51%), NeuroBo Pharmaceuticals, Inc. (2.63%), VBI Vaccines Inc. (2.65%), Edesa Biotech, Inc. (0.65%), Minerva Neurosciences, Inc. (0.56%), ABVC BioPharma, Inc. (6.14%), Benitec Biopharma Inc. (0.50%),

As of the most recent reporting period, the following stocks had the largest short interest positions: Charter Communications, Inc. ($5.01 billion), Wayfair Inc. ($4.31 billion), Tesla, Inc. ($3.42 billion), Aon plc ($3.08 billion), The Clorox Company ($2.79 billion), The Charles Schwab Co. ($2.61 billion), Moderna, Inc. ($2.01 billion), The Kroger Co. ($1.98 billion), Zillow Group, Inc. ($1.91 billion), and Snap Inc. ($1.86 billion). View all of the most shorted stocks.

Short selling TTPH is an investing strategy that aims to generate trading profit from Tetraphase Pharmaceuticals as its price is falling. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Tetraphase Pharmaceuticals occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of TTPH, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including TTPH, twice per month. The most recent reporting period available is July, 31 2020.